Study Sections: NIH's Kangaroo Politburos

I have studied the lubrication of animal joints since 1959. Between then and 1975 there were, by my count, two major discoveries. Then the government, principally the National Institutes of Health, greatly increased funding for the discipline. There have been no major discoveries since. Government support must have been misdirected-but why? At the National Science Foundation, program managers decide whom to support, and for this they get specialist advice. But reviewers who understand a scient

Written byCharles Mccutchen
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

At the National Science Foundation, program managers decide whom to support, and for this they get specialist advice. But reviewers who understand a scientist's work are often competitors in the same field. Their advice ranges from honest to artfully misleading. The project manager tries to filter out the disinformation.

NIH lets its "study sections," panels of reviewers, choose which projects to fund, and trusts that panel members will keep each other honest. Each application is described and evaluated by study section members skilled in its field. The panel discusses it, then votes to accept or reject. If it accepts, as it most often does, it votes a priority score that largely determines if the project will be funded. Subsequent stages of review are either principally symbolic or concerned with whether proposed projects fit NIH's overall plan for research. No one at NIH has suggested to me that later reviews second-guess ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies